Appendix K. Tables 3 to 5 From Report Showing Data From PP Analysis of Vaccination Outcomes

Young Adults Mis TOT Parents (Adolescent Gender) Race Young Adults Young Adults Mal Fen Mis TOT Mal Fen Mis TOT Adal	le nale ising FAL	Usual Care % (n) 41% (108) 59% (158) 266 0% (0) 100% (108) 0 108	Arm Assignment Tailored % (n) 32% (84) 68% (175) 259 0% (0) 100% (84)	Untailored % (n) 40% (115) 60% (165) 280 0 %(0)	All % (N) 38% (307) 62% (498) 100% (805)
Parents TOTAL (100% column) Gender Young Adults Mal Fer Mis TOT Parents (Adolescent Gender) Race Young Adults Young Adults Mal Fer Mis TOT Race	nale ising FAL	59% (158) 266 0% (0) 100% (108) 0	68% (175) 259 0% (0) 100% (84)	60% (165) 280 0 %(0)	62% (498) 100% (805)
TOTAL (100% column) Gender Young Adults Mal Ferr Mis TOT Parents (Adolescent Gender) Race Young Adults Young Adults Mal Ferr Mis TOT Race Wh Afrii Asia Oth Mis	nale ising FAL	266 0% (0) 100% (108) 0	259 0% (0) 100% (84)	280	100% (805)
Gender Mal Young Adults Fen Mis TOT Parents (Adolescent Gender) Mal Fen Mis TOT Race Young Adults Wh Afri Asia Young Adults Amin Oth Mis	nale ising FAL	0% (0) 100% (108) 0	259 0% (0) 100% (84)	0 %(0)	100% (805)
Young Adults Young Adults Parents (Adolescent Gender) Race Young Adults Young Adults Mal Fem Mal Fem	nale ising FAL	100% (108) 0	100% (84)		
Young Adults Ferm Mis TOT Parents (Adolescent Gender) Parents (Adolescent Gender) Race Young Adults Young Adults Afri Asia Oth Mis	nale ising FAL	100% (108) 0	100% (84)		
Young Adults Mis TOT Parents (Adolescent Gender) Race Young Adults Young Adults Mal Fen Mis TOT Asia Afri Asia Oth Mis	ssing ΓAL le	0	. ,	1000(/)	0% (0)
Young Adults Nils TOT Mal Fem Mis TOT Nils Young Adults Nils Nils Nils Nils Nils Nils Nils Nil	ΓAL le	-	0	100% (115)	100% (307)
Parents (Adolescent Gender) Parents (Adolescent Gender) Race Young Adults Young Adults Mal Ferr Mis TOT Asia Ami Oth Mis	le	108	0	0	0
Parents (Adolescent Gender) Race Young Adults Young Adults Ferm Mis Volume Ferm Mis Volume Ferm Mis Asia Asia Oth Mis			84	115	100% (307)
Parents (Adolescent Gender) Race Young Adults Young Adults Ferm Mis Volume Ferm Mis Volume Ferm Mis TOT Asia Asia Oth Mis Mis Asia					
Parents (Adolescent Gender) Mis TOT Race Young Adults Young Adults Ami Oth Mis	aalo	56% (88)	53% (92)	49% (81)	52% (261)
Young Adults Ame Young Mults Ame Young Young Yo	lale	44% (70)	47% (83)	51% (84)	48% (237)
Race Wh Afri Asia Young Adults Amu Oth Mis	sing	0	0	0	0
Vh Afri Asia Young Adults Amo Oth Mis	ΓAL	158	175	165	100% (498)
Afri Asia Young Adults Amo Oth Mis					
Young Adults Ame Oth Mis	ite	20%(22)	19% (16)	31% (36)	24% (74)
Young Adults Amo Oth Mis	can American	<1% (1)	0% (0)	0% (0)	<1% (1)
Oth Mis	an	0% (0)	0% (0)	<1% (1)	<1% (1)
Oth Mis	erican Indian	2% (2)	<1% (1)	1% (2)	2% (5)
	ier	76% (82)	80% (67)	66% (76)	73% (225)
	sing/Unknown	<1% (1)	0% (0)	0% (0)	<1%(1)
	-	108	84	115	100% (307)
					. , ,
Wh	ite	25% (39)	22% (38)	21% (34)	22% (111)
Afri	can American	0% (0)	0% (0)	0% (0)	0% (0)
Asia	an	0% (0)	<1% (1)	0% (0)	<1% (1)
Parents (Adolescent Race) Ame	erican Indian	<1% (1)	3% (5)	2% (3)	2% (9)
Oth	ier	74% (117)	75% (130)	78% (128)	75% (375)
Mis	sing/Unknown	<1% (1)	<1% (1)	0% (0)	<1% (2)
ТОТ	-	158	174	165	100% (498)
Ethnicity					
	panic	89% (96)	89% (75)	90% (104)	90% (275)
Nor	n-Hispanic	10% (11)	9% (8)	10% (11)	10% (30)
Voung Adults	sing	1% (1)	1% (1)	0% (0)	<1% (2)
тот		108	84	115	100% (307)
				-	()
Hisr	panic	90% (142)	91% (158)	90% (148)	90% (449)
Nor	n-Hispanic	10% (16)	9% (16)	10% (17)	10% (49)
Daronts (Adoloscont Ethnicity)	sing	0% (0)	0% (0)	0% (0)	0% (0)
ТОТ		158	174	165	100% (498)
Age at Baseline		/ledian Age (MED		Average	
Young Adults		23		,	
Parents (Adolescent Age)		23	22	24	23

 Table 3. Demographic Characteristics of Participants with Vaccination Data Assessed

Table 4. HPV Vaccine Uptake in Young Adults and Adolescents Across the 3 Study Arms

			Arm As	signment			
	Usua	al Care		lored	Unta	ilored	
Participant Population	# eligible for outcome assessed	% of eligible vaccinated (n)	# eligible for outcome assessed	% of eligible vaccinated (n)	# eligible for outcome assessed	% of eligible vaccinated (n))	<i>p</i> - value ^a
Young Adults						ı	
Got Any Dose of HPV During Study	108	3% (3)	84	6% (5)	115	6% (7)	0.45
Initiated the Vaccine Series ^b	85	4% (3)	66	8% (5)	93	3% (3)	0.43
Initiated the Vaccine, Series not Completed ^c	3	33% (1)	5	80% (4)	3	100% (3)	0.36
Completed the Vaccine Series, Among All Eligible ^d	99	2% (2)	79	1% (1)	102	4% (4)	0.63
Completed the Vaccine Series Among Those Initiated at Study Start ^e	23	0% (0)	18	0% (0)	22	18% (4)	0.02
Completed the Vaccine Series, Among Those Who Initiated During the Study ^f	3	67% (2)	5	20% (1)	3	0% (0)	0.36
Adolescents							
Got Any Dose of HPV During Study	158	47% (74)	175	49% (81)	165	53% (88)	0.49
Initiated the Vaccine Series ^b	93	34% (32)	115	42% (48)	95	46% (44)	0.25
Initiated the Vaccine, Series not Completed ^c	30	77% (22)	42	79% (33)	41	89% (36)	0.41
Completed the Vaccine Series, Among All Eligible ^d	140	21% (29)	158	23% (37)	151	18% (27)	0.49
Completed the Vaccine Series Among Those Initiated at Study Start ^e	65	42% (27)	60	53% (32)	70	33% (23)	0.06
Completed the Vaccine Series, Among Those Who Initiated During the Study ^f	30	23% (7)	42	21% (9)	41	12% (5)	0.41

^a P-value for three arm comparison of % vaccinated

^bDescribes those who had 0 doses at study enrollment and received at least one dose during the study period. ^cDescribes those who enrolled in the study with 0 doses, had enough time in the study period after the most recent dose to complete the series, but did not complete the series during the study period.

^dDescribes those who enrolled in the study with 0, 1 or 2 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period. ^eDescribes those who enrolled in the study with 1 or 2 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period. ^fDescribes those who enrolled in the study with 0 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period after the most recent dose to complete the series, and completed the series during the study period. Bolded p-values highlight significant or near significant results.

Table 10. Two Way Comparisons of Adolescent Vaccination Between Study Arms						
Outcome	Comparison Arms	Difference, 95% Cl	P-value ^a			
Got Any Dose of HPV During Study	Tailored vs. Usual Care	2.3 (-8.4, 13.0)	0.674			
	Untailored vs. Usual Care	6.5 (-4.4, 17.4)	0.242			
	Untailored vs. Tailored	4.2 (-6.4, 14.8)	0.439			
Initiated the Vaccine Series ^b	Tailored vs. Usual Care	7.3 (-5.9, 20.5)	0.277			
	Untailored vs. Usual Care	11.9 (-2.0, 25.8)	0.094			
	Untailored vs. Tailored	4.6 (-8.9, 18.1)	0.506			
Initiated the Vaccine, Series not Completed ^c	Tailored vs. Usual Care	1.9 (-17.7, 21.5)	0.849			
	Untailored vs. Usual Care	11.1 (-7.0, 29.3)	0.229			
	Untailored vs. Tailored	9.2 (-6.7, 25.2)	0.256			
Completed the Vaccine Series, Among All Eligible ^d	Tailored vs. Usual Care	2.7 (-6.7, 12.1)	0.574			
	Untailored vs. Usual Care	-2.8 (-11.9, 6.2)	0.541			
	Untailored vs. Tailored	-5.5 (-14.5, 3.5)	0.228			
Completed the Vaccine Series Among Those	Tailored vs. Usual Care	11.8 (-5.6, 29.2)	0.184			
Already Initiated at Study Start ^e	Untailored vs. Usual Care	-8.7 (-24.9, 7.6)	0.296			
	Untailored vs. Tailored	-20.5 (-37.2, -3.7)	0.017			
Completed the Vaccine Series, Among Those Who	Tailored vs. Usual Care	-1.9 (-21.5, 17.7)	0.849			
Initiated During the Study ^f	Untailored vs. Usual Care	-11.1 (-29.3, 7.0)	0.229			
	Untailored vs. Tailored	-9.2 (-25.2, 6.7)	0.256			

Table 5. Two Way Comparisons of Adolescent Vaccination Between Study Arms

^a P-value for the % vaccinated among the two arms denoted

^bDescribes those who had 0 doses at study enrollment and received at least one dose during the study period. ^cDescribes those who enrolled in the study with 0 doses, had enough time in the study period after the most recent dose to complete the series, but did not complete the series during the study period. ^dDescribes those who enrolled in the study with 0, 1 or 2 doses, had enough time in the study period after

the most recent dose to complete the series, and completed the series during the study period.

^eDescribes those who enrolled in the study with 1 or 2 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

^fDescribes those who enrolled in the study with 0 doses, had enough time in the study period after the most recent dose to complete the series, and completed the series during the study period.

Bolded p-values highlight significant or near significant results.